CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 24 enrolled
Drug / intervention
Belantamab mafodotin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06868667
NCT06868667Phase 3Active
CompareCT.gov

DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma

GlaxoSmithKline·interventional·Posted Mar 11, 2025·Updated Apr 23, 2026

In Brief

A Phase 3 clinical trial evaluating Belantamab mafodotin, Daratumumab, and 2 other interventions for Multiple Myeloma. Active but no longer recruiting, targeting 24 participants across 16 sites.

Detailed Summary

This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with relapsed refractory multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
Collaborators--

Timeline

Phase 3Active
2022202320242025202620272028
First PostedMar 11, 2025
Enrollment StartJul 28, 2021
Primary CompletionApr 3, 2024
Study CompletionJun 30, 2028
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 1.3 years ago

Interventions

Belantamab mafodotindrug

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate.

Daratumumabdrug

Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody.

Bortezomibdrug

Proteasome Inhibitor.

Dexamethasonedrug

Synthetic glucocorticoid with anti-tumor activity.